Compare BCAL & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCAL | VALN |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.3M | 536.9M |
| IPO Year | 2020 | 2021 |
| Metric | BCAL | VALN |
|---|---|---|
| Price | $18.38 | $6.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $20.50 | $16.00 |
| AVG Volume (30 Days) | ★ 191.8K | 137.7K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | ★ 777.27 | N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.67 | $93.87 |
| P/E Ratio | $9.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.37 | $5.43 |
| 52 Week High | $20.47 | $12.25 |
| Indicator | BCAL | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 61.74 | 28.82 |
| Support Level | $17.80 | $5.88 |
| Resistance Level | $19.31 | $6.73 |
| Average True Range (ATR) | 0.34 | 0.28 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 81.34 | 29.42 |
California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through partnerships with its clients. The company has one operating segment: Commercial Banking.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.